Eaton Corporation PLC News
Share Buybacks Seen Continuing at Record Rate in 2022
'Most of the companies have significant cash positions right now. There’s enough cash to do almost anything,' one expert says.
Disney, Wells Fargo, CVS Among Bank of America Top Picks for 2022
Bank of America named its top stock picks for 2022 in each of the S&P 500’s 11 sectors. Exxon Mobil is another selection.
Cramer's Mad Money Recap: J&J, Netflix, Nvidia, Tesla
Cramer says the clouds over Wall Street may have broken. Get ready for next week's earnings parade.
Cramer's Mad Money Recap: Pfizer, Chipotle, Southwest
When a market is this hungry for good news, even obvious news can send stocks higher, says Jim Cramer.
Eaton, Danfoss Required to Divest Assets Before Acquisition
Eaton and Danfoss agree to a proposed settlement agreement to divest certain properties.
Eaton Corp. Up on Pact to Buy Cobham Refueling Unit in $2.83B Deal
Eaton Corp. shares rise as the power-management-systems company agrees to buy Cobham Mission Systems in a $2.83 billion deal.
Best Green Energy Stocks to Buy in a Biden Presidency
The president’s detailed 'Build Back Better' plan points to a number of obvious -- and some not-so-obvious -- stock plays, including Berkshire Hathaway.
It's All Good for the Bulls: Cramer's 'Mad Money' Recap
Don't bet against progress, says Jim Cramer. Despite all the worries and woes, this is one of the best rallies he's seen.
Election Playbook: Cramer's 'Mad Money' Recap (Friday 10/30/20)
Look for more volatility next week as the presidential election, hopefully, comes to a close.
Selling Squall: Cramer's 'Mad Money' Recap (Wednesday 5/13/20)
Jim Cramer says investors need to let the froth wash out, and resist the companies with no earnings and little revenue.
Trump's Potential Return to Twitter Under Musk Hits Digital World
Digital World Acquisition, a company attempting to merge with former President Donald Trump's media group Truth Social, faces a new challenge.
Bluebird Bio's 2nd Approval Doesn't Guarantee Survival
Investors hoping for a revival at the struggling biotech might want to temper their expectations.